0001415889-24-006792.txt : 20240305 0001415889-24-006792.hdr.sgml : 20240305 20240305173050 ACCESSION NUMBER: 0001415889-24-006792 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RICHMOND TIMOTHY J. CENTRAL INDEX KEY: 0001563523 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24722557 MAIL ADDRESS: STREET 1: 1 N. WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-03052024_100336.xml X0508 4 2024-03-01 0001551152 AbbVie Inc. ABBV 0001563523 RICHMOND TIMOTHY J. 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF HR OFFICER 1 Common stock, $0.01 par value 2024-03-01 4 M 0 45700 61.36 A 89517 D Common stock, $0.01 par value 2024-03-01 4 S 0 15412 176.4 D 74105 D Common stock, $0.01 par value 2024-03-01 4 S 0 30288 177.71 D 43817 D Common stock, $0.01 par value 2024-03-01 4 S 0 9853 176.35 D 33964 D Common stock, $0.01 par value 2024-03-01 4 S 0 20127 177.71 D 13837 D Option (Right to buy) 61.36 2024-03-01 4 M 0 45700 61.36 D 2018-02-16 2027-02-15 Common Stock 45700 0 D This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.72, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. he price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.77 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.69, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.72 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. T.O. Odutayo, attorney-in-fact for Timothy J. Richmond 2024-03-05